| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H21F2N3O |
| Molecular Weight | 345.3863 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)(C)NC(=O)C1=NN(C2=C1[C@H]3CC[C@@H]2C3)C4=C(F)C=C(F)C=C4
InChI
InChIKey=NTPZXHMTJGOMCJ-WDEREUQCSA-N
InChI=1S/C19H21F2N3O/c1-19(2,3)22-18(25)16-15-10-4-5-11(8-10)17(15)24(23-16)14-7-6-12(20)9-13(14)21/h6-7,9-11H,4-5,8H2,1-3H3,(H,22,25)/t10-,11+/m0/s1
| Molecular Formula | C19H21F2N3O |
| Molecular Weight | 345.3863 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Glenmark Pharmaceuticals has developed tedalinab (also known as GRC-10693) as a potent and selective cannabinoid CB2 receptor agonist for the treatment of osteoarthritis and neuropathic pain. In April 2009, Glenmark announced that tedalinab indicated for the treatment of neuropathic, osteoarthritis and other inflammatory pain disorders had successfully completed Phase I trials in Europe. The drug was ready for phase II of trials; however, information about the further development of this drug is not available.
